Osthole inhibits GSK-3β/AMPK/mTOR pathway-controlled glycolysis and increases radiosensitivity of subcutaneous transplanted hepatocellular carcinoma in nude mice | springermedizin.de

Springer Medizin

nach oben

Strahlentherapie und Onkologie

Erschienen in:

14.11.2023 | Original Article

Osthole inhibits GSK-3β/AMPK/mTOR pathway-controlled glycolysis and increases radiosensitivity of subcutaneous transplanted hepatocellular carcinoma in nude mice

verfasst von: Hui Huang, Jie Xue, Mei-Lin Xie, Tao Xie

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Osthole possesses anti-tumor activities. However, whether osthole can have a radiosensitization effect on hepatic cancer remains unclear. Here, an HCC-LM3 cells-inoculated subcutaneous transplanted tumor was adopted to explore the effect of osthole.

Methods

The tumor-bearing mice were treated with 100 mg/kg osthole for 12 days, 4 Gy irradiation twice, or their combination. The tumor volume and weight, lactic acid content, glycolytic enzyme activities, and protein expression of glycogen synthase kinase 3β (GSK-3β), p‑GSK-3β, mammalian target of rapamycin (mTOR), p‑mTOR, AMP-activated protein kinase (AMPK), p‑AMPK, glucose transporter 1/3, and pyruvate kinase M2 were determined. The GSK-3β-overexpressed HCC-LM3 or SK-Hep‑1 cell models were also adopted to verify the effects of osthole on expression of these proteins.

Results

The tumor volume and weight, lactic acid content, and glycolytic enzyme activities in tumor tissues were lower in the osthole + radiation group than in the radiation group. Moreover, osthole could reverse the radiation-induced increments of p‑GSK-3β/GSK-3β and p‑mTOR/mTOR protein ratios and the expression of glucose transporter 1/3 and pyruvate kinase M2 proteins in tumor tissues, and increase the protein ratio of p‑AMPK/AMPK. The effects of osthole on these glycolysis-related proteins were also observed in GSK-3β-overexpressed HCC-LM3 or SK-Hep‑1 cell models.

Conclusion

Osthole has a radiosensitizing effect on subcutaneous transplanted hepatocellular carcinoma, and its mechanism may be related to inhibition of GSK-3β/AMPK/mTOR pathway-controlled glycolysis.

Anzeige

Nur mit Berechtigung zugänglich

1.

Wang L, Li J, Di LJ (2022) Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases. Med Res Rev 42:946–982CrossRefPubMed

2.

Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M (2020) GSK‑3 in liver diseases: friend or foe? Biochim Biophys Acta Mol Cell Res 1867:118743CrossRefPubMed

3.

Zhang N, Liu XJ, Liu L, Deng ZS, Zeng QX, Pang WQ, Liu Y, Song DQ, Deng HB (2018) Glycogen synthase kinase-3beta inhibition promotes lysosome-dependent degradation of c‑FLIPL in hepatocellular carcinoma. Cell Death Dis 9:230CrossRefPubMedPubMedCentral

4.

Fang GX, Zhang PL, Liu JF, Zhang X, Zhu XJ, Li R, Wang HY (2019) Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. Cancer Lett 463:11–26CrossRefPubMed

5.

Tang L, Wei F, Wu YF, He Y, Shi L, Xiong F, Gong ZJ, Guo C, Li XY, Deng H, Cao K, Zhou M, Xiang B, Li XL, Li Y, Li GY, Xiong W, Zeng ZY (2018) Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res 37:87CrossRefPubMedPubMedCentral

6.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E (2018) Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(iv238):iv255

7.

Shokoohinia Y, Jafari F, Mohammadi Z, Bazvandi L, Hosseinzadeh L, Chow N, Bhattacharyya P, Farzaei MH, Farooqi AA, Nabavi SM, Yerer MB, Bishayee A (2018) Potential anticancer properties of osthol: a comprehensive mechanistic review. Nutrients 10:36CrossRefPubMedPubMedCentral

8.

Ashrafizadeh M, Mohammadinejad R, Samarghandian S, Yaribeygi H, Johnston TP, Sahebkar A (2020) Anti-tumor effects of osthole on different malignant tissues: A review of molecular mechanisms. Anticancer Agents Med Chem 20:918–931CrossRefPubMed

9.

Chen YQ, Song HY, Zhou ZY, Ma J, Luo ZY, Zhou Y, Wang JY, Liu S, Han XH (2022) Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling. Acta Pharmacol Sin 43:1544–1555CrossRefPubMed

10.

Dai XX, Yin CT, Zhang Y, Guo GL, Zhao CG, Wang OC, Xiang YQ, Zhang XH, Liang G (2018) Osthole inhibits triple negative breast cancer cells by suppressing STAT3. J Exp Clin Cancer Res 37:322CrossRefPubMedPubMedCentral

11.

Mo Y, Wu Y, Li X, Rao H, Tian XX, Wu DN, Qiu ZP, Zheng GH, Hu JJ (2020) Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation. Eur J Pharmacol 867:172788CrossRefPubMed

12.

Lin ZK, Liu J, Jiang GQ, Tan G, Gong P, Luo HF, Li HM, Du J, Ning Z, Xin Y, Wang ZY (2017) Osthole inhibits the tumorigenesis of hepatocellular carcinoma cells. Oncol Rep 37:1611–1618CrossRefPubMed

13.

Fan K, Huang H, Zhao Y, Xie T, Zhu ZY, Xie ML (2022) Osthole increases the sensitivity of liver cancer to sorafenib by inhibiting cholesterol metabolism. Nutr Cancer 74:3640–3650CrossRefPubMed

14.

Huang H, Xue J, Xie T, Xie ML (2023) Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis. N‑S Arch. Pharmacol, vol 396, pp 683–692

15.

Qi ZG, Zhao X, Zhong W, Xie ML (2016) Osthole improves glucose and lipid metabolism via modulation of PPARα/γ-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats. Pharm Biol 54:882–888CrossRefPubMed

16.

Liu JC, Zhou L, Wang F, Cheng ZQ, Chen R (2018) Osthole decreases collagen I/III contents and their ratio in TGF-beta 1‑overexpressed mouse cardiac fibroblasts through regulating the TGF-beta/Smad signaling pathway. Chin J Nat Med 16:321–329PubMed

17.

Jia CH, Zhao Y, Huang H, Fan K, Xie T, Xie ML (2022) Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis. J Nutr Biochem 107:109038CrossRefPubMed

18.

Yu L, Sun YF, Li JJ, Wang Y, Zhu YX, Shi Y, Fan XJ, Zhou JD, Bao Y, Xiao J, Cao K, Cao PG (2017) Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism. J Exp Clin Cancer Res 36:110CrossRefPubMedPubMedCentral

19.

Feng J, Li JJ, Wu LW, Yu Q, Ji J, Wu JY, Dai WQ, Guo CY (2020) Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 39:126CrossRefPubMedPubMedCentral

20.

Feng J, Dai WQ, Mao YQ, Wu LW, Li JJ, Chen K, Yu Q, Kong R, Li SN, Zhang J, Ji J, Wu JY, Mo WH, Xu XF, Guo CY (2020) Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res 39:24CrossRefPubMedPubMedCentral

21.

Lin YZ, Zhai H, Ouyang Y, Lu ZY, Chu CB, He QT, Cao XP (2019) Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells. Cancer Cell Int 19:129CrossRefPubMedPubMedCentral

22.

Liu KX, Everdell E, Pal S, Haas-Kogan DA, Milligan MG (2021) Harnessing lactate metabolism for radiosensitization. Front Oncol 11:672339CrossRefPubMedPubMedCentral

23.

Beurel E, Blivet-Van Eggelpoel MJ, Kornprobst M, Moritz S, Delelo R, Paye F, Housset C, Desbois-Mouthon C (2009) Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem Pharmacol 77:54–65CrossRefPubMed

24.

Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B, Schimmer AD, Hedley DW (2012) Glycogen synthase kinase‑3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Plos One 7:e41102CrossRefPubMedPubMedCentral

25.

Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang EF, Gunosewoyo H, Kozikowski AP, Billadeau DD, Mukhopadhyay D (2014) Inhibition of GSK‑3 induces differentiation and impaired glucose metabolism in renal cancer. Mol Cancer Ther 13:285–296CrossRefPubMed

26.

Lin JT, Song T, Li C, Mao WF (2020) GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res 1867:118659CrossRefPubMed

27.

Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, Higashi T, Ishigaki Y, Endo Y, Takino T, Sato H, Sai Y, Miyamoto K, Motoo Y, Kawakami K, Minamoto T (2013) Aberrant glycogen synthase kinase 3beta is involved in pancreatic cancer cell invasion and resistance to therapy. Plos One 8:e55289CrossRefPubMedPubMedCentral

28.

Abrams SL, Akula SM, Meher AK, Steelman LS, Gizak A, Duda P, Rakus D, Martelli AM, Ratti S, Cocco L, Montalto G, Cervello M, Ruvolo P, Libra M, Falzone L, Candido S, McCubrey JA (2021) GSK-3β can regulate the sensitivity of MIA-PaCa‑2 pancreatic and MCF‑7 breast cancer cells to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Cells 10:816CrossRefPubMedPubMedCentral

29.

Park W, Park S, Song G, Lim W (2019) Inhibitory effects of osthole on human breast cancer cell progression via induction of cell cycle arrest, mitochondrial dysfunction, and ER stress. Nutrients 11:2777CrossRefPubMedPubMedCentral

30.

Liu B, Jin JB, Zhang ZY, Zuo L, Jiang MX, Xie CF (2019) Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1 alpha signaling pathway. Biochm. Cell Biol 97:397–405

31.

Zhang JH, Zhang YH, Mo F, Patel G, Butterworth K, Shao CL, Prise KM (2021) The roles of HIF‑1 alpha in radiosensitivity and radiation-induced bystander effects under hypoxia. Front Cell Dev Biol 9:637454CrossRefPubMedPubMedCentral

32.

Meng W, Xie BH, Yang Q, Jia CC, Tang H, Zhang XM, Zhang Y, Zhang JW, Li HP, Fu BS (2019) Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF‑B pathway. J Exp Clin Cancer Res 38:263CrossRefPubMedPubMedCentral

33.

Liu WL, Gao M, Tzen KY, Tsai CL, Hsu FM, Cheng AL, Cheng JCH (2014) Targeting phosphatidylinositide 3‑kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget 5:3662–3672CrossRefPubMedPubMedCentral

34.

Che YL, Li J, Li ZJ, Li J, Wang S, Yan Y, Zou K, Zou LJ (2018) Osthole enhances antitumor activity and irradiation sensitivity of cervical cancer cells by suppressing ATM/NF-κB signaling. Oncol Rep 40:737–747PubMedPubMedCentral

35.

Peng KY, Chou TC (2022) Osthole exerts inhibitory effects on hypoxic colon cancer cells via EIF2 alpha phosphorylation-mediated apoptosis and regulation of HIF‑1 alpha. Am J Chinese Med 50:621–637CrossRef

Titel: Osthole inhibits GSK-3β/AMPK/mTOR pathway-controlled glycolysis and increases radiosensitivity of subcutaneous transplanted hepatocellular carcinoma in nude mice
verfasst von: Hui Huang
Jie Xue
Mei-Lin Xie
Tao Xie
Publikationsdatum: 14.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2024
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-023-02173-8

Anzeige

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.